Last year's contentious U.S. presidential election is often blamed for the slowdown in dealmaking activity in the life sciences space. While the uncertainty surrounding that contest certainly had an impact, Stuart Falber and Belinda Juran see other secular trends that have made acquisitions and initial public offerings less attractive — and often impossible — forcing companies to seek new partnerships and sources of funding.
Click here to continue reading.
Originally published by Above the Law, May 12 2017.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.